CAJ | 학술논문

目的：探讨基因bcl-2和MDR-1产物在肾癌组织中表达的意义及相关关系，了解肿瘤增殖与耐药的特点。方法：采用免疫组织化学SABC法对48例肾癌和10例正常肾组织的石蜡包埋标本切片进行bcl-2和MDR-1基因产物表达的统计研究。结果：bcl-2在肾癌组织中阳性表达率为77.1%，与正常肾组织(40.0%)相比，差异有显著性意义(P＜0.05)，但其表达与肿瘤分级、分期及预后无关(P＞0.05)。MDR-1在肾癌组织和正常肾组织中均有阳性表达，与其它肾癌组织类型比较，颗粒型中显示高表达(P＜0.05)，但MDR-1表达与肿瘤病理分级及预后无关(P＞0.05)。结论：bcl-2蛋白在大多数肾癌组织中呈高表达，其表达在肾肿瘤形成中可能起作用；进一步证实MDR-1基因在肾细胞癌抵抗化疗中起作用，与bcl-2无显著相关性；肾癌化疗、放疗不敏感可能涉及MDR-1和bcl-2的双重作用。
목적：탐토기인bcl-2화MDR-1산물재신암조직중표체적의의급상관관계，료해종류증식여내약적특점。방법：채용면역조직화학SABC법대48례신암화10례정상신조직적석사포매표본절편진행bcl-2화MDR-1기인산물표체적통계연구。결과：bcl-2재신암조직중양성표체솔위77.1%，여정상신조직(40.0%)상비，차이유현저성의의(P＜0.05)，단기표체여종류분급、분기급예후무관(P＞0.05)。MDR-1재신암조직화정상신조직중균유양성표체，여기타신암조직류형비교，과립형중현시고표체(P＜0.05)，단MDR-1표체여종류병리분급급예후무관(P＞0.05)。결론：bcl-2단백재대다수신암조직중정고표체，기표체재신종류형성중가능기작용；진일보증실MDR-1기인재신세포암저항화료중기작용，여bcl-2무현저상관성；신암화료、방료불민감가능섭급MDR-1화bcl-2적쌍중작용。
Purpose:To study bcl-2 and MDR expressions in renal cell carcinoma and to evaluate its clinical significance.Methods:blc-2 and MDR expression were studied by immunohistochemical technique in 48 specimens of renal cell carcinoma tissues and in 10 normal renal tissues and their clinical significance was analyzed.Results:The positive rate of expression of bcl-2 in the renal cell carcinoma tissue was 77.1%, while it was 40.0% in the normal renal tissue(P＜0.05). However, it was not related to the tumor grade and tumor stage(P＞0.05). On the other hand, There was a positive expression of MDR1 in renal cell carcinoma and normal renal tissue. MDR1 was positively related to tumor cell type(P＜0.05). Compared with the other types of renal cell carcinoma. The granular existed higher expression. Both have no relationship with prognosis.Conclusions: bcl-2 Protein is overexpressed in the majority of renal cell carcinomas. The overexpression of bcl-2 may have a role in tumorigenesis. MDR1, an established predictor for chemo-resistance, however, has no significant correlation with bcl-1. The multidrug resistant of renal cell cancer is probably induced by double-functions of bcl and MDR1.